Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia.
Bariana, Tadbir K; Labarque, Veerle; Heremans, Jessica; Thys, Chantal; De Reys, Mara; Greene, Daniel; Jenkins, Benjamin; Grassi, Luigi; Seyres, Denis; Burden, Frances; Whitehorn, Deborah; Shamardina, Olga; Papadia, Sofia; Gomez, Keith; Van Geet, Chris; Koulman, Albert; Ouwehand, Willem H; Ghevaert, Cedric; Frontini, Mattia; Turro, Ernest; Freson, Kathleen.
; 2018 Nov 22.
Artigo em Inglês | MEDLINE | ID: mdl-30467204
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial.
Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors.
Gray platelet syndrome: proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in mice.
CK2ß regulates thrombopoiesis and Ca<sup>2+</sup>-triggered platelet activation in arterial thrombosis.
Stem cells, megakaryocytes, and platelets.
C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation.
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.
The transcription factor GATA1 regulates NBEAL2 expression through a long-distance enhancer.
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis.
Platelet bioreactor: accelerated evolution of design and manufacture.